<SEC-DOCUMENT>0001193125-24-178585.txt : 20240712
<SEC-HEADER>0001193125-24-178585.hdr.sgml : 20240712
<ACCEPTANCE-DATETIME>20240712161703
ACCESSION NUMBER:		0001193125-24-178585
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20240712
DATE AS OF CHANGE:		20240712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eliem Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001768446
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				832273741
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280784
		FILM NUMBER:		241114671

	BUSINESS ADDRESS:	
		STREET 1:		2801 CENTERVILLE ROAD 1ST FLOOR
		STREET 2:		PMB #117
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19808
		BUSINESS PHONE:		877-354-3689

	MAIL ADDRESS:	
		STREET 1:		2801 CENTERVILLE ROAD 1ST FLOOR
		STREET 2:		PMB #117
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19808
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>d760581ds3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML><HEAD>
<TITLE>S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on July&nbsp;12, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&#8194;&#8194;&#8194;&#8194;&#8194;</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-3</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ELIEM THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">83-2273741</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PMB #117 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2801 Centerville Road 1st Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wilmington, DE 19808-1609 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-877-ELIEMTX</FONT></FONT> <FONT STYLE="white-space:nowrap">(354-3689)</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aoife Brennan, M.B., Ch.B. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PMB #117 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2801 Centerville
Road 1st Floor </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wilmington, DE 19808-1609 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-877-ELIEMTX</FONT></FONT>
<FONT STYLE="white-space:nowrap">(354-3689)</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of
agent for service) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copy to: </I></B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Christopher D. Barnstable-Brown </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Scott N. Lunin </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Katharine
A. Patterson </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wilmer Cutler Pickering Hale and Dorr LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>7 World Trade Center </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>250
Greenwich Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10007 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: (212) <FONT STYLE="white-space:nowrap">230-8800</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fax: (212) <FONT STYLE="white-space:nowrap">230-8888</FONT> </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: </B>From time to time after this registration statement becomes effective.
</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check
the following box:&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis
pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&#8194;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:&#8194;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this
Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following
box.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed
to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&#8194;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until this registration statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this prospectus is not complete and may be changed. The selling
stockholders named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and the selling
stockholders named in this prospectus are not soliciting offers to buy these securities in any state or other jurisdiction where the offer or sale is not permitted. </B></FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to completion, dated July&nbsp;12, 2024
</B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g760581g28f59.jpg" ALT="LOGO" STYLE="width:1.63542in;height:0.864583in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>36,798,329 SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus relates to the resale from time to time of up to 36,798,329 shares of common stock, par value $0.0001 per share, of Eliem Therapeutics, Inc. by the selling stockholders listed on page&nbsp;7 of this prospectus, including their donees,
pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> issued to the selling stockholders in connection with our acquisition of Tenet Medicines, Inc. and our concurrent
private placement in June 2024. We are registering these shares on behalf of the selling stockholders, to be offered and sold by them from time to time. We will not receive any proceeds from the sale of the shares offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to bear all of the expenses incurred in connection with the registration of these shares. The selling stockholders will pay or
assume discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of these shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders identified in this prospectus, or their respective donees, pledgees, transferees or other <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> may offer the shares from time to time on terms to be determined at the time of sale through ordinary brokerage transactions or through any other means
described in this prospectus under the caption &#147;Plan of Distribution.&#148; The shares may be sold at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined
at the time of sale or at negotiated prices. For a list of the selling stockholders, see the section entitled &#147;Selling Stockholders&#148; on page&nbsp;7 of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire
prospectus and any amendments or supplements carefully before you make your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq
Global Market under the symbol &#147;ELYM.&#148; On July&nbsp;11, 2024, the closing sale price of our common stock on the Nasdaq Global Market was $7.07 per share. You are urged to obtain current market quotations for our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; under applicable Securities and Exchange Commission
rules and, as such, have elected to comply with certain reduced public company disclosure requirements for this prospectus and future filings. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our common stock involves significant risks. See &#147;<A HREF="#toc760581_2">Risk Factors</A>&#148; beginning on page 4 of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of the factors you should
carefully consider before deciding to purchase our common stock. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is &#8195;&#8195;&#8195;&#8195;, 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc760581_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc760581_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc760581_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc760581_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc760581_5">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc760581_6">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc760581_7">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc760581_8">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc760581_9">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc760581_10">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or incorporated by reference in this prospectus. We have
not authorized anyone to provide you with different or additional information. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or an
offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus is accurate only as of the date of this
prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock. Our business, financial condition, results of operations and prospects may have changed materially since such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in this prospectus to the &#147;Company,&#148; &#147;Eliem,&#148; &#147;we,&#148;
&#147;our&#148; and &#147;us&#148; refer, collectively, to Eliem Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc760581_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus and in the documents we incorporate by reference. This
summary does not contain all of the information you should consider before making an investment decision. You should read this entire prospectus carefully, especially the risks of investing in our common stock discussed under &#147;Risk
Factors&#148; beginning on page&nbsp;4 of this prospectus, along with our consolidated financial statements and notes to those consolidated financial statements and the other information incorporated by reference in this prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on
developing therapeutics for autoimmune-driven inflammatory diseases, including advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous
nephropathy. TNT119 is an <FONT STYLE="white-space:nowrap">anti-CD19</FONT> antibody designed to achieve broad and deep depletion of pathogenic <FONT STYLE="white-space:nowrap">B-cells</FONT> with a favorable tolerability profile and convenient
dosing regimen with the potential for subcutaneous administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of our acquisition of Tenet Medicines, Inc.
(&#147;Tenet&#148;) in June 2024 (the &#147;Acquisition&#148;), our strategy is to develop TNT119 for a range of autoimmune-mediated diseases, where we believe CD19-targeted approaches have clear biological rationale, where we can potentially
achieve clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> and where we can introduce product candidates that can be meaningfully differentiated in the market. TNT119&#146;s lead indication is
in systemic lupus erythematosus, the most common type of lupus and an autoimmune disease in which the immune system attacks its own tissue, causing widespread inflammation and tissue damage in affected organs including joints, skin, brain, lungs,
kidneys and blood vessels. In systemic lupus erythematosus, the underlying pathology involves the production of autoantibodies by autoreactive B cells and the formation of immune complexes that contribute to inflammation and tissue damage. CD19 is a
protein expressed on the surface of these B cells, and it plays a role in B cell activation, proliferation and survival. TNT119 is designed to target and deplete CD19-expressing B cells known to produce autoantibodies, thereby providing a novel
approach to the potential treatment of systemic lupus erythematosus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal mailing address is PMB #117, 2801 Centerville Road 1st Floor, Wilmington, DE 19808-1609. Our workforce is currently working
remotely, and we do not currently have a physical office in the United States. Our telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-877-ELIEMTX</FONT></FONT> <FONT STYLE="white-space:nowrap">(354-3689).</FONT>
Our website is www.eliemtx.com. Information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquisition and Private Placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;27, 2024, we completed the Acquisition of Tenet. The Acquisition was effected in accordance with the terms of an Agreement and Plan of Merger and Reorganization (the &#147;Acquisition Agreement&#148;), dated as of April&nbsp;10, 2024, by
and among us, Tango Merger Sub, Inc., a Delaware corporation and our wholly owned subsidiary (&#147;Transitory Subsidiary&#148;), Tenet, and, solely in his capacity as Tenet equityholder representative, Stephen Thomas, providing for the acquisition
of Tenet by us through the merger of Transitory Subsidiary into Tenet, with Tenet surviving as our wholly owned subsidiary. At the closing of the Acquisition, we issued an aggregate of 5,560,047 shares of our common stock to Tenet equityholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Acquisition Agreement, certain of the selling stockholders entered into <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements pursuant to which, subject to specified exceptions, they agreed not to transfer their shares of common stock issued in connection with the Acquisition for the
<FONT STYLE="white-space:nowrap">180-day</FONT> period following the closing of the Acquisition. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;27, 2024, immediately following the closing of the Acquisition, we issued and
sold 31,238,282 shares of our common stock at a price of $3.84 per share in a private placement to several accredited institutional investors pursuant to a Securities Purchase Agreement, dated as of April&nbsp;10, 2024 (the &#147;Securities Purchase
Agreement&#148;), by and among us and certain of the selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a detailed description of the transactions with the
selling stockholders contemplated by the Acquisition Agreement and the Securities Purchase Agreement and the securities issued pursuant thereto, see the section entitled &#147;Selling Stockholders&#148; in this prospectus. We filed the registration
statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> of which this prospectus forms a part, to fulfill our contractual obligations under a registration rights agreement we entered into with certain of the selling stockholders and to
provide for the resale by the selling stockholders of the shares of common stock offered hereby. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Common Stock Offered by Selling Stockholders </P></TD>
<TD>36,798,329 shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of shares in this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market Symbol </P></TD>
<TD>&#147;ELYM&#148; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc760581_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our common stock involves significant risks. Before deciding whether to invest in our common stock, you should carefully consider
the risks and uncertainties described under the section entitled &#147;Risk Factors&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> our most recent Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> Exhibit 99.3 to our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on June&nbsp;27, 2024 and other filings we
make with the SEC from time to time, which are incorporated by reference herein in their entirety, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future, together with the other
information in this prospectus and in the documents incorporated by reference in this prospectus. The occurrence of any such risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial,
could cause our business, prospects, operating results and financial condition to suffer materially. In such event, the trading price of our common stock could decline, and you might lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc760581_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference in this prospectus include &#147;forward-looking statements&#148; within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements, other than statements of historical
fact, contained in or incorporated by reference in this prospectus, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are
forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;target,&#148; &#147;potential,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;continue&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements
contain these identifying words. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this prospectus reflect our current views with respect to future events or to our
future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or
achievements expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the plans, intentions and expectations described in the forward-looking statements we make. You are cautioned that these forward-looking statements are subject to risks, uncertainties
and assumptions that are referenced in the sections entitled &#147;Risk Factors&#148; in this prospectus and in the documents incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the information incorporated by reference herein completely and with the understanding that our actual future results may
be materially different from what we expect. The forward-looking statements contained in this prospectus are made as of the date of this prospectus, and we do not assume any obligation to update any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A statement contained in a document incorporated by reference into this
prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or in any other subsequently filed document which is also incorporated in
this prospectus modifies or replaces such statement. Any statements so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus incorporates by reference statistical and other industry and market data that we obtained from industry publications and research, surveys and
studies conducted by third parties. All of the market data used in this prospectus and the information incorporated by reference herein involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data.
Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
Our estimates of the potential market opportunities for our product candidate include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size
and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc760581_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are filing the registration statement of which this prospectus forms a part to permit the holders of the shares of our common stock
described in the section entitled &#147;Selling Stockholders&#148; to resell such shares. We are not selling any shares under this prospectus, and we will not receive any proceeds from the sale or other disposition of shares of our common stock held
by the selling stockholders and offered hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders will pay any discounts, commissions, fees of underwriters,
selling brokers, dealer managers or similar securities industry professionals and expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing
of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, filing and printing fees, listing fees and fees and expenses of our
counsel and our accountants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc760581_5"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2024, we entered into an Agreement and Plan of Merger and Reorganization, dated as of April&nbsp;10, 2024 (the &#147;Acquisition
Agreement&#148;), by and among us, Tango Merger Sub, Inc., a Delaware corporation and our wholly owned subsidiary (&#147;Transitory Subsidiary&#148;), Tenet Medicines, Inc. (&#147;Tenet&#148;), and, solely in his capacity as Tenet equityholder
representative, Stephen Thomas, providing for the acquisition of Tenet by us through the merger of Transitory Subsidiary into Tenet, with Tenet surviving as our wholly owned subsidiary (the &#147;Acquisition&#148;). On June&nbsp;27, 2024, we
completed the Acquisition in accordance with the terms of the Acquisition Agreement, and we issued an aggregate of 5,560,047 shares of our common stock to Tenet equityholders as consideration for our acquisition of Tenet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2024, we also entered into a securities purchase agreement (the &#147;Securities Purchase Agreement&#148;), with certain of the selling
stockholders (the &#147;PIPE Investors&#148;), pursuant to which we agreed to issue and sell an aggregate of 31,238,282 shares of our common stock at a price of $3.84 per share in a private placement (the &#147;Private Placement&#148;), contingent
upon, among other things, the closing of the Acquisition. The Private Placement was completed immediately following the closing of the Acquisition on June&nbsp;27, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Private Placement, on April&nbsp;10, 2024, we entered into a registration rights agreement (the &#147;Registration Rights
Agreement&#148;) with the PIPE Investors, pursuant to which we agreed to file a registration statement with the SEC covering the resale of the shares of common stock sold in the Private Placement. We agreed to file such registration statement within
45 days following the closing of the Private Placement. The Registration Rights Agreement includes customary indemnification rights in connection with the registration statement providing for the resale of such shares. Pursuant to the Acquisition
Agreement, the Tenet equityholders who received stock consideration in the Acquisition could elect to become a party to the Registration Rights Agreement. We refer to both the PIPE Investors and the former Tenet equityholders as selling stockholders
in this prospectus. The registration statement of which this prospectus forms a part has been filed in accordance with the Registration Rights Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary descriptions of the Acquisition Agreement, the Securities Purchase Agreement and the Registration Rights Agreement do not purport to be
complete and are qualified in their entirety by reference to the full text of such documents, which were filed as exhibits to the registration statement of which this prospectus forms a part and are incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below sets forth, to our knowledge, information concerning the beneficial ownership of shares of our common stock by the selling stockholders as of
June&nbsp;30, 2024. The information in the table below with respect to the selling stockholders has been obtained from the respective selling stockholders. When we refer to the &#147;selling stockholders&#148; in this prospectus, we mean the selling
stockholders listed in the table below as offering shares, as well as their respective donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest.</FONT></FONT> The selling
stockholders may sell all, some or none of the shares of common stock subject to this prospectus. See &#147;Plan of Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the table
below, the number of shares of common stock beneficially owned prior to the offering for each selling stockholder includes (i)&nbsp;all shares of common stock held by such selling stockholder as of June&nbsp;30, 2024, (ii) all shares of common stock
such selling stockholder has the right to acquire within 60 days of June&nbsp;30, 2024, (iii) all shares of common stock acquired by such selling stockholder in the Acquisition and (iv)&nbsp;all shares of common stock purchased by such selling
stockholder in the Private Placement. The percentages of shares owned before and after the offering are based on 66,785,449 shares of common stock outstanding as of June&nbsp;30, 2024, which includes the outstanding shares of common stock offered by
this prospectus. In computing the number of shares of common stock beneficially owned by a selling stockholder and the percentage ownership of that selling stockholder, we deemed outstanding shares of common stock that such selling stockholder has a
right to acquire within 60 days of June&nbsp;30, 2024. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other selling stockholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment
power with respect to our common stock. Unless otherwise indicated below, to our knowledge, each selling stockholder named in the table has sole voting and investment power with respect to the shares of common stock beneficially owned by it, except
to the extent authority is shared by spouses under applicable law. Unless otherwise indicated below, the address of each beneficial owner listed below is c/o Eliem Therapeutics, PMB&nbsp;#117, 2801 Centerville Road 1st Floor, Wilmington, DE
19808-1609. The inclusion of any shares in this table does not constitute an admission of beneficial ownership for any selling stockholder named below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock<BR>Beneficially&nbsp;Owned&nbsp;Prior<BR>to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Being Offered</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of<BR>Common&nbsp;Stock to<BR>be&nbsp;Beneficially Owned<BR>After Offering (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Percentage</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Percentage</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,459,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,268,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,190,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Pontifax (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,206,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,206,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd.&nbsp;(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,904,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,904,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janus Henderson Biotech Innovation Master Fund Limited (5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,253,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,253,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, LP (6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,261,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,261,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boxer Capital, LLC (7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,603,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,603,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Basil Thomas (8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Daley Bonificio (9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Naveen Manu Daryani (10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We do not know when or in what amounts a selling stockholder may offer shares for sale. The selling
stockholders might not sell any or might sell all of the shares offered by this prospectus. Because the selling stockholders may offer all or some of the shares pursuant to this offering, and because there are currently no agreements, arrangements
or understandings with respect to the sale of any of the shares, we cannot estimate the number of the shares that will be held by the selling stockholders after completion of the offering. However, for purposes of this table, we have assumed that,
after completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 2,479,872 shares of common stock issued to Sera Medicines, LLC (&#147;Sera Medicines&#148;) in
connection with the closing of the Acquisition; (ii) 23,521,757 shares of common stock held by RA Capital Healthcare Fund, L.P. (&#147;RA Healthcare&#148;), which consists of 973,000 shares of common stock issued in connection with the closing of
the Acquisition and 11,949,171 shares of common stock issued in the Private Placement; (iii) 1,226,497 shares of common stock held by RA Capital Nexus Fund, L.P. (&#147;Nexus Fund&#148;); (iv) 841,087 shares of common stock held by a separately
managed account (the &#147;Account&#148;); (v) 483,679 shares of common stock held by RA Capital Nexus Fund II, L.P. (&#147;Nexus Fund II&#148;); (vi) 2,866,375 shares of common stock held by RA Capital Nexus Fund III, L.P. (&#147;Nexus Fund
III&#148;), which consists of 1,807,000 shares of common stock issued in connection with the closing of the Acquisition and 1,059,375 shares of common stock issued in the Private Placement and (vii) 40,000 shares of common stock issuable pursuant to
stock options held by Andrew Levin, our Executive Chairman and a member of our board of directors, for the benefit of RA Capital Management, L.P. (&#147;RACM&#148;) that are exercisable within 60 days of June&nbsp;30, 2024. Sera Medicines is
controlled by RACM, and RA Healthcare and Nexus Fund III collectively own approximately 81% of the outstanding equity interests of Sera Medicines. RACM is the investment manager for RA Healthcare, Nexus Fund, the Account, Nexus Fund II, and Nexus
Fund III. The general partner of RACM is RA Capital Management GP, LLC. The general partner of RA Healthcare is RA Capital Healthcare Fund GP, LLC. The general partner of Nexus Fund is RA Capital Nexus Fund GP, LLC. The general partner of Nexus Fund
II is RA Capital Nexus Fund II GP, LLC. The general partner of Nexus Fund III is RA Capital Nexus Fund III GP, LLC. Dr.&nbsp;Peter Kolchinsky and Mr.&nbsp;Rajeev Shah are the managing members of RA Capital Management GP, LLC, RA Capital Healthcare
Fund GP, LLC, RA Capital Nexus Fund GP, LLC, RA Capital Nexus Fund II GP, LLC and RA Capital Nexus Fund III GP, LLC and have the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
power to vote or dispose of the shares held by Sera Medicines, RA Healthcare, Nexus Fund, Account, Nexus Fund II and Nexus Fund III. The address of the persons and entities listed above is 200
Berkeley Street, 18th Floor, Boston, Massachusetts 02116. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 3,312,625 shares of common stock issued to Pontifax (Israel) VI L.P. in the Private Placement
and (ii) 1,893,755 shares of common stock issued to Pontifax (Cayman) VI L.P. in the Private Placement. The General Partner of Pontifax (Israel) VI L.P. and Pontifax (Cayman) VI L.P. is Pontifax VI GP L.P. The General Partner of Pontifax VI GP L.P.
is Pontifax Management IV GP (2015)&nbsp;Ltd. Mr.&nbsp;Tomer Kariv and Mr.&nbsp;Ran Nussbaum are the managing members of the Partnerships. The address of the persons and entities listed above is 14 Shenkar Street, Herzlia 46725, Israel.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,904,785 shares of common stock issued to Deep Track Biotechnology Master Fund, Ltd. (&#147;Deep
Track Fund&#148;) in the Private Placement. Deep Track Capital, LP (&#147;Deep Track Manager&#148;) is the investment manager of Deep Track Fund. Deep Track Capital GP, LLC (&#147;Deep Track Partner&#148;) is the general partner of Deep Track
Manager and David Kroin is the managing member of Deep Track Partner. The address of each of Deep Track Fund, Deep Track Manager, Deep Track Partner and Mr.&nbsp;Kroin is 200&nbsp;Greenwich Ave, 3rd Floor, Greenwich, Connecticut 06830.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,253,988 shares of common stock issued to Janus Henderson Biotech Innovation Master Fund Limited
in the Private Placement. Such shares may be deemed to be beneficially owned by Janus Henderson Investors US LLC (&#147;Janus&#148;), an investment adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser for
Janus Henderson Biotech Innovation Master Fund Limited (the &#147;Janus Fund&#148;) and has the ability to make decisions with respect to the voting and deposition of the shares subject to the oversight of the board of directors of the Janus Fund.
Under the terms of its management contract with the Janus Fund, Janus has overall responsibility for directing the investments of the Janus Fund in accordance with the Janus Fund&#146;s investment objective, policies and limitations. The Janus Fund
has one or more portfolio managers appointed by and serving at the pleasure of Janus who make decisions with respect to the disposition of the shares of common stock offered hereby. The address for Janus is 151 Detroit Street, Denver, CO 80206. The
portfolio managers for the Janus Fund are: Andrew Acker, Daniel S. Lyons and Agustin Mohedas. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,261,393 shares of common stock issued to Samsara Biocapital, LP (&#147;Samsara LP&#148;) in the
Private Placement. Samsara BioCapital GP, LLC (&#147;Samsara LLC&#148;) is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr.&nbsp;Srinivas Akkaraju, MD, Ph.D. has voting and investment power
over the shares held by Samsara GP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. The
address for Samsara LP is 628&nbsp;Middlefield Road, Palo Alto, CA 94031. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,603,190 shares of common issued to Boxer Capital, LLC (&#147;Boxer Capital&#148;) in the Private
Placement. Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph C. Lewis is the sole indirect owner of Boxer Asset Management Inc. Boxer Capital, Boxer Asset Management Inc. and Joseph C. Lewis have shared powers to vote (or
direct the vote) and/or to dispose (or direct the disposition) of the shares of common stock held by Boxer Capital. Boxer Asset Management Inc. and Joseph C. Lewis disclaim beneficial ownership over the shares of common stock held by Boxer Capital
except to the extent of their pecuniary interest therein. The principal address for Boxer Capital is 12860 El Camino Real, Suite&nbsp;300, San Diego, CA 92130. The principal address for Boxer Asset Management and Mr.&nbsp;Lewis is Cay House, EP
Taylor Drive N7776, Lyford Cay, New Providence, Bahamas. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 103,907 shares of common stock issued to Dr.&nbsp;Thomas in connection with the closing of the
Acquisition. Dr.&nbsp;Thomas was elected to our board of directors in connection with the closing of the Acquisition. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 103,907 shares of common stock issued to Dr.&nbsp;Bonificio in connection with the closing of the
Acquisition. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 92,361 shares of common stock issued to Dr.&nbsp;Daryani in connection with the closing of the
Acquisition. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationships with Selling Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>RA Capital Management </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrew Levin, who is our Executive
Chairman and a member of our board of directors, is a Partner and Managing Director of RACM, which, with certain of its affiliated funds, is a selling stockholder. Additionally, RACM is affiliated with Sera Medicines, which is a selling stockholder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RACM is also a party to an investor rights agreement (the &#147;Investor Rights Agreement&#148;), as amended in March 2021, with Eliem and certain other
holders of our redeemable convertible preferred stock and common stock. The Investor Rights Agreement provides the holders of our redeemable convertible preferred stock with certain registration rights, including the right to demand that we file a
registration statement or request that their shares be covered by a registration statement that we are otherwise filing. The registration of shares of our common stock pursuant to the exercise of certain registration rights would enable the holders
to sell such shares without restriction under the Securities Act, when the applicable registration statement is declared effective. We have agreed to pay the registration expenses, other than underwriting discounts and commissions, of the shares
registered pursuant to certain demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sera Medicines </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sera Medicines was founded on October&nbsp;1, 2023 by RACM and certain members of Tenet&#146;s management team, including Stephen Thomas, a member of our board
of directors, William Bonificio and Naveen Daryani, each of whom are selling stockholders. RACM holds approximately 81% of Sera Medicine&#146;s equity interests and members of Tenet&#146;s management hold approximately 19% of Sera Medicine&#146;s
equity interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consulting Agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the closing of the Acquisition, each of Dr.&nbsp;Thomas, Dr.&nbsp;Bonificio and Dr.&nbsp;Daryani entered into a consulting agreement with us. Pursuant to their respective consulting agreements, Dr.&nbsp;Thomas is paid a fixed
consulting fee equal to $10,000 per month, and Dr.&nbsp;Bonificio and Dr.&nbsp;Daryani are paid hourly consulting fees. In addition, each of Dr.&nbsp;Thomas, Dr.&nbsp;Bonificio and Dr.&nbsp;Daryani were paid a transaction bonus in the amount of
$150,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, at the closing of the Acquisition, our board of directors granted to each of Dr.&nbsp;Thomas, Dr.&nbsp;Bonificio and
Dr.&nbsp;Daryani 200,750 restricted stock units (&#147;RSUs&#148;), pursuant to our 2021 Equity Incentive Plan. Of the RSUs granted to each of Dr.&nbsp;Thomas, Dr.&nbsp;Bonificio and Dr.&nbsp;Daryani, 100,375 RSUs are subject to time-based vesting
with 50% of such RSUs vesting on January&nbsp;1, 2025, 25% of such RSUs vesting on March&nbsp;27, 2025 and the remaining 25% of such RSUs vesting on June&nbsp;27, 2025, subject to continued service. The remaining 100,375 RSUs granted to each of
Dr.&nbsp;Thomas, Dr.&nbsp;Bonificio and Dr.&nbsp;Daryani are subject to performance-based vesting and vest subject to the satisfaction of performance conditions, including the achievement of specified operational milestones on or before
September&nbsp;30, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Thomas was also elected to our board of directors in connection with the closing of the Acquisition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain Legacy Tenet Relationships </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tenet is a party to a
services agreement (the &#147;Blackbird Services Agreement&#148;) with Blackbird, an entity controlled by RACM, a selling stockholder. Under the terms of the Blackbird Services Agreement, Blackbird provides consulting services in connection with
Tenet&#146;s clinical trials, including study strategy, clinical operations and patient operations. In consideration for services provided under the Blackbird Services Agreement, Tenet pays Blackbird a yearly service fee of $360,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tenet is also party to a services agreement (the &#147;Sera Services Agreement&#148;) with Sera Services, Inc. (&#147;Sera Services&#148;), an affiliate of
RACM and Sera Medicines, each of which are selling stockholders. Tenet&#146;s clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development and professional services functions, including the services of Tenet&#146;s executive officers, are currently performed through Sera Services pursuant to the Sera Services Agreement.
Pursuant to the Sera Services Agreement, Tenet compensates Sera Services for the costs associated with clinical development and professional services plus a markup. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc760581_6"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders, which as used herein includes donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution
or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted by applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by
them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act, amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also
may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these
securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other
financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial
institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to
the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through
agents. We will not receive any of the proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the
shares in open market transactions in reliance upon Rule 144 under the Securities Act of 1933, provided that they meet the criteria and conform to the requirements of that rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein
may be &#147;underwriters&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the
Securities Act. Selling stockholders who are &#147;underwriters&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and
public offering prices, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective
amendment to the registration statement that includes this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if
applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption
from registration or qualification requirements is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the selling stockholders that the
anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this
prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any
broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities
laws, relating to the registration of the shares offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the selling stockholders to use
commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of (1)&nbsp;such time as all of the shares covered by this
prospectus have been disposed of pursuant to and in accordance with such registration statement and (2)&nbsp;the date on which all of the shares may be sold without restriction pursuant to Rule 144 of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc760581_7"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of our common stock offered hereby has been passed upon for us by Wilmer Cutler Pickering Hale and Dorr LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc760581_8"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this prospectus by reference to the Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2023 have been so incorporated in reliance on the report of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on
the authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Tenet Medicines, Inc. as of
December&nbsp;31, 2023 and for the period from November&nbsp;8, 2023 (inception) to December&nbsp;31, 2023 incorporated by reference in this prospectus by reference to Eliem Therapeutic, Inc.&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> dated June&nbsp;27, 2024 have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent auditor, as stated in their report. Such financial statements are incorporated by reference in reliance upon the
report of such firm given upon their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc760581_9"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the
Internet at the SEC&#146;s website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at www.eliemtx.com. Our website is not a part of this prospectus and is not incorporated by reference
in this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a
registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement
for further information about us and our consolidated subsidiaries and our securities. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not
intended to be comprehensive and are qualified by reference to these filings and the exhibits attached thereto. You should review the complete document to evaluate these statements. You can obtain a copy of the registration statement from the
SEC&#146;s website. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc760581_10"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important information to you by
referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this
prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to
determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File
<FONT STYLE="white-space:nowrap">No.&nbsp;001-40708)</FONT> and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not
deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration
statement is terminated or completed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001768446/000095017024038023/elym-20231231.htm">Form <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2023, filed with the SEC on March&nbsp;
28, 2024, as amended by <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001768446/000119312524122192/d831708d10ka.htm">Amendment No.<U></U>&nbsp;1</A> thereto, filed with the SEC on April&nbsp;29, 2024;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001768446/000095017024059995/elym-20240331.htm">March<U></U>&nbsp;31, 2024</A>, filed with the SEC on May&nbsp;15, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001768446/000119312524070333/d784366d8k.htm">March<U></U>&nbsp;19, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001768446/000119312524092520/d737147d8k.htm">April<U></U>&nbsp;11, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001768446/000119312524159994/d839370d8k.htm">June<U></U>&nbsp;12, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001768446/000119312524169077/d788381d8k.htm">June<U></U>&nbsp;26, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001768446/000119312524170599/d692630d8k.htm">June<U></U>&nbsp;27, 2024</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1768446/000119312521235064/d120929d8a12b.htm">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on August&nbsp;
3, 2021, as the description therein has been updated and superseded by the description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1768446/000095017022002998/elym-ex4_3.htm">Exhibit 4.3</A> to our Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;7, 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Eliem Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PMB #117
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2801 Centerville Road 1st Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wilmington, DE 19808-1609 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-877-ELIEMTX</FONT></FONT> <FONT STYLE="white-space:nowrap">(354-3689)</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g760581g36q99.jpg" ALT="LOGO" STYLE="width:2.44984in;height:1.29514in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>36,798,329 SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:180pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:180pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;, 2024 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;14. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the various expenses to be incurred in connection with the sale and distribution of the securities being
registered hereby, all of which will be borne by Eliem Therapeutics, Inc. (except any discounts, commissions, fees of underwriters, selling brokers, dealer managers and similar securities industry professionals and expenses incurred by the selling
stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of the shares). All amounts shown are estimates except the SEC registration fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Item</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;15. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary is qualified in its entirety by reference to the complete Delaware General Corporation Law (&#147;DGCL&#148;), our
Amended and Restated Certificate of Incorporation (&#147;Certificate&#148;) and our Amended and Restated Bylaws (&#147;Bylaws&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is
threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the
corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person
reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify
such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or
she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have
determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the DGCL provides, generally, that our Certificate may contain a provision eliminating or limiting the personal
liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, provided that such provision may not eliminate or limit the liability of (i)&nbsp;a director for any breach of the
director&#146;s duty of loyalty to the corporation or its shareholders, (ii)&nbsp;a director for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;a director under section 174 of
the DGCL or (iv)&nbsp;a director for any transaction from which the director derived an improper personal benefit. No such provision may eliminate or limit the liability of a director for any act or omission occurring prior to the date when such
provision became effective. Our Certificate includes such a provision. The effect of this provision is to eliminate the personal liability of directors for monetary damages or actions involving a breach of their fiduciary duty of care, including any
actions involving gross negligence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate and Bylaws provide that we will indemnify our directors and officers to the
fullest extent permitted by the DGCL, except we may modify the extent of such indemnification by individual contracts with our directors and executive officers. Our Bylaws also provide that we are not required to indemnify any director or executive
officer in connection with any proceeding initiated by such person unless (i)&nbsp;such indemnification is expressly required to be made by applicable law, (ii)&nbsp;the proceeding was authorized by our board of directors or (iii)&nbsp;such
indemnification is provided by us, in our sole discretion, pursuant to the powers vested in us under the DGCL or any other applicable law. Our Bylaws also provide that that the right of directors and officers to indemnification shall be deemed a
contractual right and will not be exclusive of any other right now possessed or hereafter acquired under any statute, provision of the certificate of incorporation, bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Upon
the approval of our board of directors, our Bylaws also permit us to purchase and maintain insurance on behalf of any person required or permitted to be indemnified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have entered into indemnification agreements with our directors and officers that require us, among other things, to indemnify
them against certain liabilities that may arise by reason of their status or service, so long as the indemnitee acted in good faith and in a manner the indemnitee reasonably believed to be in or not opposed to the best interests of us, and, with
respect to any criminal action or proceeding, the indemnitee had no reasonable cause to believe his or her conduct was unlawful. We also maintain director and officer liability insurance to insure our directors and officers against the cost of
defense, settlement or payment of a judgment under specified circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;16. Exhibits. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporation By Reference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Form</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SEC File No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filed&nbsp;Herewith</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;2.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1768446/000119312524092520/d737147dex21.htm">Agreement and Plan of Merger and Reorganization, dated as of April&nbsp;10, 2024, by and among Eliem Therapeutics, Inc., Tango Merger Sub, Inc., Tenet Medicines, Inc. and, solely in his capacity as the Company Equityholder Representative, Stephen Thomas </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-40708</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4/11/2024</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1768446/000119312521244913/d392719dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-40708</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8/12/2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1768446/000119312521232117/d105292dex34.htm">Amended and Restated Bylaws of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-257980</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8/2/2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1768446/000119312524092520/d737147dex104.htm">Securities Purchase Agreement, dated April&nbsp;10, 2024, by and among Eliem Therapeutics, Inc. and the investors party thereto </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-40708</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4/11/2024</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1768446/000119312524092520/d737147dex105.htm">Registration Rights Agreement, dated April&nbsp;10, 2024, by and among Eliem Therapeutics, Inc. and the parties thereto </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-40708</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4/11/2024</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d760581dex51.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d760581dex231.htm">Consent of PricewaterhouseCoopers LLP</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d760581dex232.htm">Consent of Deloitte&nbsp;&amp; Touche LLP</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d760581dex51.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit&nbsp;5.1 filed herewith) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on the signature page of this registration statement) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d760581dexfilingfees.htm">Filing Fee Table</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment or by a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT>
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment
pursuant to Rule <FONT STYLE="white-space:nowrap">24b-2</FONT> of the Exchange Act for any exhibits or schedules so furnished. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)(1) To file,
during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) To include any
prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933, as amended, or the Securities Act; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the
prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth
in this registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low
or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission, or the Commission, pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or
any material change to such information in this registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided, however</I>, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii)
do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the
Securities Exchange Act of 1934, as amended, or the Exchange Act, that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this registration statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) That, for the purposes of determining any liability under the Securities Act, each post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at the time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to any purchaser: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date
the filed prospectus was deemed part of and included in the registration statement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) each prospectus required to be filed pursuant
to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x)&nbsp;for the purpose of providing the information required by
Section&nbsp;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration
statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement
will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the
registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated
by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the
registrant pursuant to the indemnification provisions described herein, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wilmington,
State of Delaware, on July 12, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ELIEM THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Aoife Brennan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Aoife Brennan, M.B., Ch.B.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the undersigned officers and directors of Eliem Therapeutics, Inc. hereby severally constitute and appoint Aoife Brennan, M.B., Ch.B. and
Andrew Levin, M.D., Ph.D., and each of them singly, our true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> with full power to any of them, and to each of them singly, to sign for us and
in our names in the capacities indicated below the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed herewith and any and all amendments (including post-effective amendments) to said Registration Statement, and
generally to do all such things in our name and on our behalf in our capacities as officers and directors to enable Eliem Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the
Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following
persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Aoife Brennan</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aoife Brennan, M.B., Ch.B.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;12, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Andrew Levin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Andrew Levin, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Executive Chairman of the Board of Directors</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Principal Financial Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;12, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Emily Pimblett</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Emily Pimblett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Accounting Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Principal Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;12, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Judith Dunn</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Judith Dunn, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;12, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Liam Ratcliffe</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Liam Ratcliffe, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;12, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Adam Rosenberg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Adam Rosenberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;12, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Simon Tate</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Simon Tate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;12, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Stephen Thomas</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stephen Thomas, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;12, 2024</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d760581dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g760581dsp30a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 212 230 8800 (t) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 212 230 8888 (f) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">wilmerhale.com
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;12, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eliem Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PMB #117 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2801 Centerville Road 1<SUP
STYLE="font-size:75%; vertical-align:top">st</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmington, DE 19808-1609 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is furnished
to you in connection with a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#147;Registration Statement&#148;) filed with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act
of 1933, as amended (the &#147;Securities Act&#148;), for the registration of an aggregate of 36,798,329 shares of Common Stock, $0.0001 par value per share (the &#147;Shares&#148;), of Eliem Therapeutics, Inc., a Delaware corporation (the
&#147;Company&#148;). All of the Shares are being registered on behalf of certain stockholders of the Company (the &#147;Selling Stockholders&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are acting as counsel for the Company in connection with the registration for resale of the Shares. We have examined signed copies of the
Registration Statement filed with the Commission. We have also examined and relied upon minutes of meetings of the stockholders and the Board of Directors of the Company as provided to us by the Company, stock record books of the Company as provided
to us by the Company, the Amended and Restated Certificate of Incorporation and the Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Company, each as restated and/or amended to date, and such other documents as we have
deemed necessary for purposes of rendering the opinions hereinafter set forth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination of the foregoing documents, we have
assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents
and the legal competence of all signatories to such documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion below, insofar as it relates to the Selling Stockholders&#146;
shares being fully paid, is based solely on a certificate of the Chief Accounting Officer of the Company confirming the Company&#146;s receipt of the consideration called for by the applicable resolutions authorizing the issuance of such shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We assume that the appropriate action will be taken, prior to the offer and sale of the Shares, to register and qualify the Shares for
sale under all applicable state securities or &#147;blue sky&#148; laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion herein as to the laws of any state or
jurisdiction other than the General Corporation Law of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g760581dsp30b.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g760581dsp30a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 12, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eliem
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly
authorized and are validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is understood that this opinion is to be used only in connection with
the offer and sale of the Shares while the Registration Statement is in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as to the matters
expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in
any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act and
to the use of our name therein and in the related prospectus under the caption &#147;Legal Matters.&#148; In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the
Securities Act or the rules and regulations of the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wilmer Cutler Pickering Hale and Dorr LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WILMER CUTLER PICKERING HALE AND DORR LLP</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d760581dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> of Eliem Therapeutics,
Inc.<B> </B>of our report dated March&nbsp;28, 2024<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>relating to the financial statements, which appears in Eliem Therapeutics, Inc.&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023. We also consent to the reference to us under the heading<B> </B>&#147;Experts&#148;<B><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></B>in such
Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seattle, Washington<B> </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;12, 2024<B><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP></B> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>d760581dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT AUDITORS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
consent to the incorporation by reference in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> of our report dated May&nbsp;16, 2024, relating to the financial statements of Tenet Medicines, Inc., appearing in the
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of Eliem Therapeutics, Inc. filed with the SEC on June&nbsp;27, 2024. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;12, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>d760581dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eliem
Therapeutics, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered and Carry Forward Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Security</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Class</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Calculation<BR>or Carry<BR>Forward<BR>Rule</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Amount<BR>Registered</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Unit</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Maximum<BR>Aggregate<BR>Offering<BR>Price</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee<BR>Rate</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Amount of<BR>Registration<BR>Fee</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Carry<BR>Forward</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Form<BR>Type</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Carry<BR>Forward<BR>File</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Number</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Carry<BR>Forward</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Initial<BR>Effective<BR>Date</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">Filing Fee<BR>Previously<BR>Paid In<BR>Connection<BR>with&nbsp;Unsold<BR>Securities&nbsp;to<BR>be Carried<BR>Forward</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Newly Registered Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees to Be</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common Stock, $0.0001 par value per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Other</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">36,798,329(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$6.66(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$245,076,871.14(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">0.00014760</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$36,174</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Previously</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Carry Forward Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Forward</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Securities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;">Total Offering Amounts&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$245,076,871.14(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$36,174</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;">Total Fees Previously Paid&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;">Total Fee Offsets&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">$36,174</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock will be offered for resale by the selling stockholders pursuant to the prospectus
contained in the registration statement to which this exhibit is attached. The registration statement registers the resale of an aggregate of 36,798,329 shares of the Registrant&#146;s common stock. Pursuant to Rule 416 under the Securities Act of
1933, as amended (the &#147;Securities Act&#148;), the shares of common stock being registered hereunder include such indeterminate number of shares of common stock as may be issuable upon stock splits, stock dividends, or other distribution,
recapitalization or similar events. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This estimate is made pursuant to Rule 457(c) of the Securities Act solely for purposes of calculating the
registration fee. The maximum offering price per share and maximum aggregate offering price are based upon the average of the high and low sales prices of the Registrant&#146;s common stock on July&nbsp;9, 2024, as reported on the Nasdaq Global
Market. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g760581dsp30a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g760581dsp30a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M([=?+L[?0O"NJPS60MEMV$DD\<F]W7R]JJQ-@V-WP)-X[F_X*6Z@_P 0]/\
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M](^(-SJ-MX.UC^Q-#TWPJ^D2^&/"/AC0Y/%+26]E]ITR:YOKRZO9YKB:_F=
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M_B?5K[3VTZQDUK4-;\4ZFJZ18K/=7264$"L]T+:5YB+8*QL&Q[90 4 % !0
74 % !0 4 % !0 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g760581dsp30b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g760581dsp30b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M$GQIX@\(ZA\-[#0M/T6]'CKQQ_PA=S-J]U>V_P#9;S>%_$GB.VU"WBLX'^V
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M9:74>K36\]_XATNT26+0)K:WUR1?M%RAV:=/>6B79('V=KB,3;-XR :0\?\
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M3Z#:6SVEGXHT33_[4)TW6##/=?:K*6:X@NBUKND06*^<;!L7=3_9WN[KP_\
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M>'Y);2_7Q)I=_)IVF6.L7VHZ3JFCV[?:])L;&_B%_=206Z:=-;W,5X8O)WN
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MSI(X88D620B)8XP$!MY6#;RL:&B_#O2]#;26M[R]D.CZ[_;T'F_9_P!Y<_\
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M6D1F6QF1#>076E>,-8MYHVF1EW120R121AB;?(-OD9(^"?A:;P]?^&=3GO\
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M6DZ;H]O-/Y?GS0:99PV44LWE(B>:T<"LVQ%7). !P #6H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
F "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g760581g28f59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g760581g28f59.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[1D>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "@< 5H  QLE1QP"   "   < E  %%!A='1E<G-O;BP@2V%T:&%R:6YE
M.$))300E       0 (SNT:)GDWV:^;W7WY;K=SA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!8            "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 &
M   !  ( 8     $  CA"24T$)@      #@             _@   .$))300-
M       $    >#A"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #-0    8              %,   "=
M  $                          0              G0   %,
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   %,     4F=H
M=&QO;F<   "=    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   !3     %)G:'1L;VYG    G0    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 4P"= P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MU%SKL3  %..7$-W6%SW_ $/S/9_UQ=_]9/\ Q/\ 4O\ PK?_ .>WKE/\5?\
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3
M #8    ! #A"24T$(@     !4DU- "H    (  @!$@ #     0 !   !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    %0   +"':0 $     0   ,@   #T    8
M  $   !@     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z
M,#<Z,3$@,#4Z-#(Z,#8 4&%T=&5R<V]N+"!+871H87)I;F4       .@ 0 #
M     ?__  "@ @ $     0   )V@ P $     0   %,         !@$#  ,
M   !  8   $:  4    !   !0@$;  4    !   !2@$H  ,    !  (   (!
M  0    !   !4@("  0    !              !(     0   $@    !.$))
M30/]       (          #_X0%:17AI9@  34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    5    L(=I  0    !    R
M /0   !@     0   &     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C R-#HP-SHQ,2 P-3HT,CHP-@!0871T97)S;VXL($MA=&AA<FEN90
M     Z !  ,    !__\  * "  0    !    G: #  0    !    4P
M   & 0,  P    $ !@   1H !0    $   %" 1L !0    $   %* 2@  P
M  $  @   @$ !     $   %2 @( !     $              $@    !
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M*"@H*"@H*"@H*"@H_\  $0@!! 'K P$B  (1 0,1 ?_$ !P   $$ P$
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M!(C,GSK7: [Z'DNT>&5<ZOP*>1VJ[9RW<W^BW[U$S#DQ569<_N)PS?\ -?\
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MO8]5I#P>O'#<='8F2<N4V T?S+IB1(X_..!Z@#L%*V$ON7[ ;BRY6GXO8A3
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ME=)3LIXBT7&]]RLQLT; +S350C:2YHL/,V5FW(K48&4N )OT6">MIH(B'/(
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MVM=+K)()[#R3\W8C6YEIVTE)#%(R*7FM+/"2+$;ZCZH;=$BQL=QV&@R]68F
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G0 A"$ (0A "$(0 A"$ (0A "$(0 A"$ (0A "$(0 A"$ (0A ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g760581g36q99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g760581g36q99.jpg
M_]C_X  02D9)1@ ! 0$ 0 !   #_[1D@4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "@< 5H  QLE1QP"   "   < E  %%!A='1E<G-O;BP@2V%T:&%R:6YE
M.$))300E       0 (SNT:)GDWV:^;W7WY;K=SA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!0!7V         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 $ 5
M]@ !  ( 0!7V  $  CA"24T$)@      #@             _@   .$))300-
M       $    >#A"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #-0    8              %,   "=
M  $                          0              G0   %,
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   %,     4F=H
M=&QO;F<   "=    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   !3     %)G:'1L;VYG    G0    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 4P"= P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M         0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:  P# 0 "$0,1 #\ ]522224I))))2DDDDE*22224I))))2PA
M.HC15\_)=C8YL:-Q$0#Q_:2430LLLK)9C4FUXD#0 =RJN#U095IJ+-CH);K(
M*ACV'JF.]EXVEI'N;XH7V,=,JLRMWJ6,:=FD $^U.H;'YF+BD2)#^;=C< N-
M^MW6NHX^>S%Q[#34&!^YNA<27?G?N^U0MS+"_P!2VX[R="71_FK7P*L/K6-&
M=6S(=28;8>8/\IJ<(\)L^IBGD]X'' \$F7U9ZK=E=*.1FN ])SFNM,-!: '>
MH[_.V*]A=7PLYSV8[Y<S\W@D?O-_DK&^L[F8N+CX&,T5TOW.+6Z"&1M;_GNW
MKGJK;*;&VUN+;&&6N[@I" EJLES)Q2CC/JX?YQ](E-&JS^C=1;U##;88%C?;
M8T=G?^1?]-:291NFWQ@PX^E6_P#_T/54DDDE*22224I))))2DDDDE*22224L
MHN:U[2UP!!Y!$A1M>YM+WM&YP!+6^)CA9O2\[(R+WLM@MB9 B$0.JTR (C^\
MAJ^L73&90PZF.8POV"P !FZ=O^;N_/6GEULLHL8[5I:=P'*RA]5L89@R&VN]
M(.WBF.\[MN[]Q8GUE^L/4&9[\+&L--5,!Q U<2&N=N=^Y[DX1!-18)998H2.
M4?W.!IW=-RWVETM<''Z1,+9Z$TX%K&-.[U7 6^!GV_\ 06=T&[,SV6UN'J.I
MVG?H"0=WTO\ -708F ^@G)R! J!<ULZR$^1KTEKX,=F.2*+ZVTL?CLL;K=22
M0P<EI^E_U*XLYCNS1'F5U5MK[;'6//N/*IV]-PKGEUE0+CR1+9_S48GA%%',
M1.2?%'TK_4_J(_:+L<C:+6$@=I;[F_\ 0]1=O"Y;H>'CT9U8IK#20Z7#4\._
M.74SV3)?./,,^*,ARTXG]V7Y/__1]42T0,K+QL2DW95K*:F_2L>0T#_.6,?K
MS]5@_9]N;/$[+(_SO3V))$9'8/02%B=>^M/3>A/IKS6V.=>'.9Z;0[1NW=NW
M.9^\M/%S<7-I&1B6MOK=P^MP<%P/^-3^E=/_ *EOY:T0+-+L4!*?"7KNJ?6'
M%Z?B493FN>,@!U;! ,.&[<[]WZ2M=*ZG1U+$;E4@M:XD%KN01])JR\^KHK^A
M81ZO:**A76&6$P0XL^BUW]1KEH]&9TYG3JSTUS7XIDUO:9G7W.W?G>]'T\/]
M9AX<HR$G^:=&/))9O4>O=)Z7IG93*7D2&$R^/WO39O>JN-]<OJUE6"JK.KW'
M0!X=6#_:M;6Q"F01D18#NIM$@01(U!69C_6#HV39971F5/?2US[ '1M:P[7N
M=N_-9N04 3LZ:CL:/+N5A?\ /;ZL"WTOMS-W$[7[?^W=GI_]-:61U?IN+BC+
MOR:Z\=PEEA<-KO\ B_W_ .PBHPEU#DYW4,IEUKM[FMJ+H8-! _ZM8&?B_M&W
M[4]WIW6 ;X&AT]OM6^SZR_5+J-WHC*J=:_V@O:YDS[=N^UM;4#(Z/F4O(8SU
M&?FN;X*2) _JM+F<&3KZHM/H]PZ:VS%H_G;(<^X_2T_-_P"DK.1E91IL_2O)
M(.A)(_S4,].NQ;S9>(=8/:)F!_Y/VJOU+*.+B.>WZ;O:SXG\Y.T)8>*4(4?3
M&+5NZVVJO:UN^[N/S0L]_5^H/,BP,'[K6B%3)DZI*01 :<LLB=W8Z1]8<C#S
M&69)]6GA\ ;@#^<U=[^T<;[)]L]5OH;=WJ3[8\5Y4M!K<_\ 8M@+;/LGK,(,
M>WZ-N[;_ "?H[_\ A$V4!Q ^(;&'F)B&2!%CAEKVT?_2AU;J5/7OK2:>I9/V
M?I>-8]C=8 :S=[F_\+>]OT__ $FNC _Q9^CZ,XNV(W>[=_V[]/\ Z:YC*Q,7
MH7UNL;U;'%W3[7O>-S=P-=A=ML;^]Z#_ .=79LP/J ^H7M9@FHB=Q<T?]4Y.
M+:G0$*XN'^H\=TWJ./T#ZU-9TS)^T=,O>QCH,@L?M^E_+H>[Z?\ Z46G_C3_
M *5T_P#J6_EK1\+-^J.9UEG3NF]';D'>(R6@!H ^E=[_ '[*T'_&I_2^G?U+
M?RUI=0J)O+#3U-GZ]_\ B0Z9_7H_\\V*STOJAZ3_ (NZLY@!L96\5 \;WVOJ
MK_Z;MZK?7O\ \2'3/Z]/_GFQ%PNFV]3_ ,6]>)2-UQ8Y]3?%S+GV[?\ KFW8
MAT6Z>W"_EXW ^J]?U<R7W=1^LF4RS(<\AE5SCKHUSKK-GTG_ )FS^0M;K.-]
M0,S"L;B7X^-E-:3597+?='M;8WZ#V/6;]3;?JRYMN#UNBEN2'DU6W#:"/:QU
M+G?FOK>W\]=%U.KZ@].QG7V48CR!+*J]KGN/[K&-=_TOH)QW73-9-.-J?XMN
MM7Y%%_2\AQL^S 68Y)DAD['U_P!2M^WTUS/U<Z2WK'UBLP[7.;CS8_(#3M+F
M,<W]'_;N])=Q]3KNDYC;\WIW3/L#!^C]4Q^D_.<UNS]S:U<S_B^_\5F5_P 5
M;_Y\K2O=0E1RD#A=[ZR_4SH5?1,J_$QVX]V-4ZUEC"==@WN:[<[W;V-7/?4;
MH=/7'V.ZBYUV)@ "G&+B&[K"Y[_H?F>S_KB[_P"LFOU?ZE_X5N_\]O7*?XJ]
M,?J/]>O\CT 32V,Y>U,VC^O?U6Z3@]+;U# I&/978UCVM)VN:_=^:[\_?M6Y
M]4^IVO\ JIC9-Q-ME8=623J=CW55[G?U-B'_ (QH_P";3X_TM?Y2I?XOF-?]
M5J6O (<^T$$:'WN2_1U6R)."R?5Q.IC7LZFQ]=]<;((^?[O[JYKZYX3,5N**
MRXM>73)&A&S;_P!4Y=)E]2Z=TNEWI[2XF!6PC<YRY'K?5<KJE0%C6-;6=[&M
M&HTV_2_MI^,'BL?*YG-3A[1@3Q9'#2225ARD^ ]E>;0^RLW,#VEU8$DB?H[/
MSW_R%ZI V\:1PO-OJYCUY/6<:NQQ;#M[2.2Y@]5K?^BO2YTE09#ZX>;?Y0'[
MMGE_>_Z+_]/T7J/2>G=5H]#.H;>P:MW<@_R7M][/["P3_BU^KN_=-X'[@L$?
M]3O_ .FNM21M<)R H%SNF=%Z7T>ES<"AM0.KW"7/='[SW;['?U5E=7I^K/6\
MBMF?7D674-EC!3DL(:\_2<UE?T=]7TUTICX++K:[_G'D.CVG#I /:?5R4E F
M[O5AD=*Z1USIE6+<PV8M%A;6)<PAU)LQ7>[Z?YMBN=/Z=C].PV86(W915(8T
MDN(DE[O<[^4Y8M&(:L%N96;6Y(ZBX:/?&Q^<ZJUOI;MGI/I<Y_\ -_\ "H/3
MGY=F1C>K>&9_K$Y-<VNL(D^I791_,U8^S^:?_-?S/I))()!%^ET.J_4_H75K
M#=DX^R\_2NJ.QQ_K;?8_^VQ4L?\ Q=?5RAX>]EE\:AMC_;_X$*U&H.IZ1@69
M%EA?EN;Z]]]MC:Q#;'-;?M_P7YE=?Z#U+/3]6S_2#KR3]GQ&Y618W%'4;:RY
MKK& U>C?:QNYSO6^S[]OT[/YO_@DM4@S H3>JIHIQZF445BNI@VL8T0T#^2U
M9?3OJOT?I>8_.PZG,O>',<XO<X$/+7O]KG?O-69=9D"NS[)8[]D_:JVFUSGE
M@K])WK;+6_IOLGVOT&;Z[/3_ )[_  7J*=&0^A]&0<F< 9L.<PV&IC3CVU;?
M5L_G,;[2ZK_NO7D)( -&B[^?7BVXME&60*<D>@X$Q/J?HMC7?O/W[%2Z'T;I
M72?M%?3JGU!SVBW>7$$AN]IK=9])NVS\Q9>6^K,IRLFQUCL>KJ6.66;GM:*M
MN'ZEC=COYG^=?O\ ^NHM]M@R;FWV6MZ=]L8VUX<Z!7]DJ=6UUGTV8[\G^=?_
M *3^=_G+$E &JMV>J=*PNK8AQ,UA?22'$ ENK?H^YJAA]*QNF]..!T]IKK ?
MLDET.?.NY_\ +65E'%^SU''RWLQ?6>6'(-GV=_M'Z/[2UU;V5;_?C66665^I
M_->I^B]/5Z-8ZWIM-CFO;.X 6.-CB&N<UCO5>VM]K+&,WUO>S?Z:2"#PU?I>
M*ZY1DLZA56]A:&L#M>.7;O\ J4!=G]8.CNSZFVTP+ZIV@F-P_=7(OQLFNSTW
MU.;9,!I:9*FA($.3GPRC,_NR:PZ9?E6[<1A>\Z[!_P!5_(5T?4WK>T.+:P?W
M=^O_ )!=CT?I;.GXS6$3<X VN\7>']5BTN.4V6:5Z,V/D(<-S^9Y+ZN_5;*P
MLYF;F.:#4#Z=;#.I#F[G._J.76I1HE'9,,R3?9LQP0CC.,?+($'_  G_U/54
ME\JI)*?JI)?*J22GZJ27RJDDI^JEF]2V_;>ESM_I+HW;I_HV7_-Q^=_67S.D
MDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDR^5DDE/U4DOE5))3]5)+Y5224__
MV3A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !#
M %, -@    $ .$))300B      %234T *@    @ " $2  ,    !  $   $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M?@$R  (    4    G $[  (    5    L(=I  0    !    R    /0   !
M     0   $     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-SHQ,2 P-3HT,CHU,0!0871T97)S;VXL($MA=&AA<FEN90       Z !
M  ,    !__\  * "  0    !    G: #  0    !    4P         & 0,
M P    $ !@   1H !0    $   %" 1L !0    $   %* 2@  P    $  @
M @$ !     $   %2 @( !     $              $@    !    2     $X
M0DE- _T       @          /_A 5I%>&EF  !-30 J    "  ( 1(  P
M  $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @   !4   "PAVD !     $   #(
M    ]    $     !    0     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#(T.C W.C$Q(# U.C0R.C4Q %!A='1E<G-O;BP@2V%T:&%R:6YE
M       #H $  P    '__P  H ( !     $   "=H , !     $   !3
M      8! P #     0 &   !&@ %     0   4(!&P %     0   4H!*  #
M     0 "   " 0 $     0   5(" @ $     0              2     $
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M*"@H*"@H*"@H*"@H*"C_P  1" &% M\# 2(  A$! Q$!_\0 '    00# 0
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M$(0 A"$ (0A "$(0 A"$ (0A "$(0 A"$ (0A "$(0 A"$ (0A "$(0 A"$
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M0A "$(0 A"$ (0A "$(0 A"$ (0A "$(0 A"$ (0A "$(0 A"$ (0A "$(0
MA"$ (0A "$(0 A"$ (0A "$(0 A"$ (0A "$(0 D0470"A(0#Q0D>;60>"@
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M"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A"
M$(0@$>;,)4(>2I9/:W*&/0%0R&2@94[DD&J4Z-1$F)72F.GFL!HPG7T*N*RK
M=4Y,S6C+?@K#Q%A?!-8\8R/F5:U4!ILN8@YNBUCX<O(E2()(P1SXI:5YCGCL
M+V<.*E+NX-%CM[U4WQ(5CSU/?IVN!UCC!)W6^=]BZICKKC=GZ=QIY>\/.^Q=
ME&,JI(]7 [0R>F;/&YKG$9NBTU=LU3U&=SII@<MM+>I;DR!KR;<$]LP/(J.S
M1+A&3VBO6[&TNOL]1\WJ724.S-/3QQO;-,2&@:VZ>A;\R <DW>@FUBH[6/\
M'A[1A,IVP,RM)(;U44TY80+!9DK"XN=?DM%C)R31@^]6D=F.3^BT4OM;C,D]
M(&%D>DU]+]'+C!&)ZG,XD9CK9/DF$M1*T BSB?G49D#7$6X+H@K/FN1.?Y))
MJ=L;[-<3I=(R$2W#B191;P%XT*S*IW=;Z5T1A^CS+FG;,/VAY+=;&VJWVSF(
M/\LH6966,[1_B6CW1<>(6;@4!..8>VXUJ(Q_B"2C1Z&#)?R6[OB>04>]<W4
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M""+A-+VCB4H&5I 49;F1%&_P2 @\$MPF $< BQZ*:%CLP1F";9+9*%BW"5,
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M9A^5CX6G?AUR#T=X*P9 3;*L&II14-R.C#P#>Q*0E1X.?"LBH\_XMLI5-;4
M3P#N\K]/0M=A6QU9)"\^40>=SOZE?\^S\$KG9Z-C@[C<\?G38=GJ6!I:VBC:
M";V!_>NCZRH\U?Q^_#F]C-G9<.J:E\CX7![ !E!Z^A=Y30EK&#30*)E)NKED
M8:3T*RH6O!;?@L93['H8</TU5$S&]PA,C:67OS3\[6Z.-BD)#O-6$CLB]41-
M:0\FZDX"ZCRR7-OI3FY@;.5C-#FR@<BI+IH:SF$A>VVA0NDP,P!(L4K90> *
MCLTNN>"4&,*"U$A&;@F;LWXA >#P*;F=U4E7$D##;DE8+736OT[Q3VN!OE*$
M4(772C@BPZ)>"@D$(0@(Y1W"EB'L94<V<M(;U1%G;$<W'5"4B5@RW6/3-(G>
M2=-?I4C)..8IUV,[W"Z"A7.O=G--;&0.(2$@W<WY4W,_J5)#B2'1#3<V36O!
MOF*<7, TXH*!S"Z]BD8TLO<WNDS&^AT2EX'G%!U'/:7,L-$P-+-2;V3VO'5!
M<S6Y4"AN^;T*>'9M F@1G@ E<+#N<4!&9@'%EC<**2+>NN .FJD(9<W\Y)<@
MZ<%%LLX)HPZC"S)EMNA;J%ANPI[2>]'QZ+=YG'@2HRQQ)N-%>+.>>%/X.(Q[
M!W@54V:*S6$\-= N/;W05;.*TXEHJIH8"]T;@!UT5>5V%S0O:-SEN/?#UK:+
M//S<>GI&L)N+)N7FF=YI.;0)V\&7BMXM''+$U\"$IK8W'@4H<TJ=CXQ>Y^96
M<E1GU?AK<3_BCAXCZ5HMVYTHL>)"W%:7R;QK=1FT'QI:&CS;LOB!.;KXK*RC
M@_P9NS4)8RHN0;EOVK;U)#8_C4%/&*<.R-R7Z*8-<_1VH463&+_ QAS #JIX
MF$-/!1AN5W"P"?O !:ZM%F\8:(I3F LI2=W3AQX6'!,:PF^BP<7K&04<@WF4
MM(' Z:K1%92432[2U[1)-'E?=T5OE!7%769CU>9<0[LI(+0."P#=:P6CS^3)
M2>F#G:) =+)NO-')6HY&V*4("%-&?;\B@H)1P;= (MJ@20AT0-4%'H0FD+9
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M;GAMFL@L+DVY+LMFGP/%1N&-;;+>S;=4,)3*"V9G$W:3B4(;8B6HUOT<5?>
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M5[)U8:W=8;6DWUM&X_8H*;9*N,XWF%UH;U,;A]BO8(5OK/\ !S_]-C_[,J[
M-EC!5TLLE#4L+)FNNX.%K$&ZLS*8_,!U4J%24W(Z\''6!-)C +\0EL;VY)R%
M0Z!I8"AA/-.0@!!0A ($EBG(4V10@&FO%#4J%!((0A "$(0 FF]TY" $(0@!
M"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A"
M$(0@!(A" %R7:BT'9&>X!]DC^E"$))NS0 ;&4-@!K)_F.74!"$(!"$( 0A"
M$(0@!"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A" $(0@!"$(
G 0A" $(0@!"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A" $(0@/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
